Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 251Lymphoma 128Leukemia, Myeloid, Acute 103Lymphoma, Non-Hodgkin 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Neoplasms, Plasma Cell 91Myelodysplastic Syndromes 91Leukemia 79Hodgkin Disease 78Lymphoma, Large B-Cell, Diffuse 66Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Mantle-Cell 59Lymphoma, Follicular 57Neuroblastoma 44Burkitt Lymphoma 44Lymphoma, Large-Cell, Immunoblastic 40Lymphoma, B-Cell, Marginal Zone 37Recurrence 34Myeloproliferative Disorders 32Hematologic Neoplasms 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Immunoglobulin Light-chain Amyloidosis 29Leukemia, Myeloid, Accelerated Phase 25Leukemia, Myeloid, Chronic-Phase 24Congenital Abnormalities 24Leukemia, Myelomonocytic, Chronic 23Graft vs Host Disease 23Dendritic Cell Sarcoma, Interdigitating 21Waldenstrom Macroglobulinemia 20Melanoma 20

Interventions

Ipilimumab 17tremelimumab 9Nivolumab 9durvalumab 8pembrolizumab 6Paclitaxel 5Carboplatin 4Capecitabine 4Bevacizumab 4lenvatinib 3spartalizumab 2balstilimab 2Radiotherapy 2Radiation 2Pemetrexed 2Oxaliplatin 2Doxorubicin 2Docetaxel 2Cisplatin 2CTLA-4 Antigen 2Blood Specimen Collection 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1relatlimab 1poly ICLC 1osimertinib 1folfirinox 1eribulin 1envafolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Melphalan × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡